ESYT3

Across TCGA pan-cancer cohorts, ESYT3 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated ESYT3 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ESYT3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ESYT3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

ACC, ESCA, and COAD are the cancer types where ESYT3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
ESCA	OS	Median	II,III,IV	0.183	0.707	<.001	36	view →
COAD	DFS	Median	II,III,IV	0.028	0.744	<.001	34	view →
UCEC	DFS	Median	All	1.000	0.598	.001	34	view →
LUSC	OS	Median	II,III,IV	0.184	0.745	<.001	27	view →
BLCA	OS	Median	III,IV	0.181	0.686	<.001	18	view →
DLBC	DFS	Median	II,III,IV	0.022	0.837	<.001	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
READ	OS	Median	II,III,IV	0.187	0.653	.030	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	III,IV	1.000	0.338	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

ESYT3–ACC (DFS)

Open the ACC breakdown →